{"organizations": [], "uuid": "1ce73fb2f8bec58cdb1da56ed5729e1a046e3fe2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aspen-pharmacare-says-hy-normalise/brief-aspen-pharmacare-says-hy-normalised-heps-increased-by-26-pct-idUSFWN1QQ00L", "country": "US", "domain_rank": 408, "title": "BRIEF-Aspen Pharmacare Says HY ‍Normalised HEPS Increased By 26 Pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T13:21:00.000+02:00", "replies_count": 0, "uuid": "1ce73fb2f8bec58cdb1da56ed5729e1a046e3fe2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aspen-pharmacare-says-hy-normalise/brief-aspen-pharmacare-says-hy-normalised-heps-increased-by-26-pct-idUSFWN1QQ00L", "ord_in_thread": 0, "title": "BRIEF-Aspen Pharmacare Says HY ‍Normalised HEPS Increased By 26 Pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aspen pharmacare holdings ltd", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Aspen Pharmacare Holdings Ltd:\n* ‍NORMALISED HEADLINE EARNINGS PER SHARE INCREASED BY 26% TO 872 CENTS FOR SIX MONTHS ENDED 31 DECEMBER 2017​\n* ‍HY REVENUE GENERATED BY GROUP GREW 11% TO R21,9 BILLION​\n* ‍PERFORMANCE IN SECOND HALF WILL BENEFIT FROM ADDITIONAL RIGHTS TO AZ ANAESTHETICS FOR FULL SIX MONTHS​\n* ‍ANTICIPATED H2 OPERATING CASH FLOWS WILL REMAIN STRONG; CONVERSION RATE OF 100% OF OPERATING PROFITS IS TARGETED FOR FULL FY Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T13:21:00.000+02:00", "crawled": "2018-03-09T14:30:50.039+02:00", "highlightTitle": ""}